Female BALB/c mice were immunized intranasally with the mouse pneumonitis biovar of Chlamydia trachomatis and subsequently challenged in the ovarian bursa (C. trachomatis immunized, C. trachomatis challenged). protein), and 60-kDa cysteine-rich proteins and 75-and 100-kDa chlamydial components could be demonstrated. However, reactivity to the 60-kDa heat shock protein was only observed 22 days after challenge. In addition, this group of animals mounted a significant immune response to chlamydial antigens, as shown by a lymphocyte proliferation assay, compared with the sham-immunized nonchallenged mice. After intrabursal challenge, there was no C. trachomatis shedding from the vagina in the C. trachomatis-immunized, C. trachomatis-challenged animals, while 63% of the sham-immunized, C. trachomatis-challenged mice had a positive C. trachomatis culture. In addition, histological sections from the genital tract showed, at 2 weeks postchallenge, a marked acute inflammatory reaction in the sham-immunized, C. trachomatis-challenged animals while in the C. trachomatis-immunized, C. trachomatis-challenged mice there was minimal inflammatory reaction. When the animals were mated, only 12% of the mice from the sham-immunized, C. trachomatis-challenged mice were fertile. In contrast, 94 and 80% of the sham-immunized, nonchallenged and C. trachomatis-immunized, C. trachomatis-challenged mice, respectively, were fertile.
Pelvic inflammatory disease is a major medical problem in Western countries, affecting women during their reproductive age (48) . This clinical entity is poorly defined and can present itself as a mild or even asymptomatic form that resolves in a matter of weeks or as an acute episode that may lead to the demise of the patient or long-term sequelae. Among the long-term sequelae, ectopic pregnancy and infertility are significant medical problems having a major impact at the individual and public health levels (2, 4, 5, 12, 13) . Early treatment of pelvic inflammatory disease may lead to complete recovery with no damage to reproductive function. Unfortunately, a significant number of cases are asymptomatic, mild, or misdiagnosed, and thus no therapeutic measures are taken to resolve the problem. For these reasons, the most effective approach to the prevention of the sequelae is to develop a vaccine that can be administered before the individual becomes sexually active.
The etiology of pelvic inflammatory disease is probably multifactorial, and the symptomatology and long-term sequelae may be the result of the interaction between the pathogenic microorganism or microorganisms and the immune system of the patient (5) . Among the bacterial pathogens, Chlamydia trachomatis appears to play a leading role in pelvic inflammatory disease. For example, seroepidemiological studies in Western high titers of antibody to C. trachomatis in women with tubal infertility (4, 12, 13, 28, 29) and ectopic pregnancy (2, 5, 7, 39) . Also, chlamydial DNA has been detected more frequently in the cervixes of infertile women (26.3%) than in a control group of fertile individuals (12.5% (38) .
Vaccination with C. trachomatis has been explored with humans and several animal models, including monkeys and mice, with the whole organism or subunit vaccines (9-11, 35, 42, 43, 47) . Early attempts to vaccinate with the whole nonviable organism resulted in serovar-specific protection that lasted for only 12 to 18 months, and some of the vaccinated individuals upon reexposure developed more severe disease than the controls (11, 35) . In an attempt to avoid the negative effects that resulted when the whole organism was used as the immunogen, Taylor et al. (42) immunized monkeys orally with the chlamydial major outer membrane protein (MOMP) and showed that it was partially effective in protecting against a challenge. Tuffrey et al. (43) were also able to show that parental immunization of mice with recombinant MOMP reduced the duration of colonization and the severity of the salpingitis but conferred no protection against infertility.
Experimental models of salpingitis have been established by inoculation of the mouse strain of C. trachomatis (mouse pneumonitis [MoPn] ) into the upper reproductive tract of female Swiss mice (22, 40, 41) or by inoculation of progesterone-treated inbred mice with human strains of C. trachomatis (45) . In these models, after the acute infectious episode, a significant number of mice developed oviductal pathology that resulted in unilateral or bilateral infertility. Both (6, 22, 27) .
Animals. Six-to 7-week-old BALB/c (H-2d) female mice (Simonsen Laboratories, Gilroy, Calif.) were used in this study.
The mice were kept in cubicles equipped with negative air pressure (15 to 20 air changes per min).
The experimental plan was carried out in three stages. In the first, stage, the effects of different doses of C. trachomatis
MoPn on the fertility rates of the inoculated mice were determined. In the second step, the intranasal dose required to induce a strong immune response while producing minimal morbidity in the mice was established. In the final stage, the ability of intranasal immunization to protect against infertility when the mice were challenged in the ovarian bursa was assessed.
To determine the effects of different doses on the fertility rates, we first inoculated groups of 10 female BALB/c mice in the left ovarian bursa with 10' to 107 C. trachomatis MoPn inclusion-forming units (IFU) per mouse. The right ovarian bursae received mock-infected HeLa-229 cell extracts processed with the same protocol employed for purification of the EBs. As a control group, 10 mice were inoculated with mock-infected HeLa-229 cell extracts in both the left and right ovarian bursae. The animals were anesthetized with methoxyflurane and inoculated by making a lateral flank incision to expose the ovary (40, 41 sham immunized with HeLa-229 cell extracts but not challenged (sham immunized, nonchallenged). Six weeks after intrabursal challenge, groups of four or five female mice were housed together with proven breeder male mice for 18 days. Pregnancy was assessed by measuring the weight gained during the mating period, and the mice that were considered pregnant were sacrificed. After the first mating, female mice that did not gain weight were mated again with male mice that had been successfully mated with another group of female mice. Pregnancy was again monitored by weight gain, and pregnant mice were sacrificed. Finally, all animals were sacrificed 25 days from the start of the second mating. At the time that the female mice were sacrificed, the number of embryos in each uterine horn was counted. The mice that had an embryo or embryos in both uterine horns were considered fertile.
The experiment was performed three times, and mice were sacrificed at regular intervals to characterize the histopathological changes and the lymphoproliferative immune response.
Cultures for C. trachomatis MoPn. Vaginal swab samples for the isolation of C. trachomatis MoPn were cultured in McCoy cell monolayers as previously described (22) .
Histology. Tissues were fixed in buffered formalin and processed by standard techniques (22) .
Immunoassays. Blood was collected from each group of mice according to procedures described elsewhere and stored at -20°C for future immunoassays (22) . (26) .
Western blotting (immunoblotting) was performed as previously described with C. trachomatis EBs as the antigen (22, 36) .
The serum samples, diluted 1:100 with PBS-Tween 20 or a 1:2 dilution of vaginal secretions, were incubated for 1.5 h at room temperature or overnight at 4°C, and the nitrocellulose membranes were processed as before (22, 36) . As positive controls, a 1:500 dilution of mouse monoclonal antibodies against the C. MoPn (generated in our laboratory) were also tested. In vitro neutralization assay. The in vitro neutralization assay was performed as previously described with centrifugation to infect HeLa-229 cell monolayers in shell vials (21, 22, 27) . The neutralization titer was the dilution at which a 50% decrease in the number of IFU relative to that of the control serum was observed.
Detection of ASCs. Spleen cells isolated from two experimental or control mice were used to enumerate chlamydiaspecific antibody-secreting cells (ASCs) by the ELISPOT assay with the following modifications (24, 37) . in a 5% CO2 incubator and processed as described previously (24, 37) .
LPA. The lymphocyte proliferation assay (LPA) was performed as previously described (1, 23) . The spleens from two mice from each group were aseptically removed, teased into a single-cell suspension, and enriched for T cells by passage over a nylon wool column (14) . On the basis of these data, we decided to use 104 C.
trachomatis MoPn IFU per mouse as the immunization dose for the protection experiments and to challenge the mice at 60 days postimmunization. Protection against infertility. To assess the effectiveness of intranasal immunization to protect against infertility, three groups of mice (C. trachomatis-immunized, C. trachomatis challenged; sham immunized, C. trachomatis challenged; and sham immunized, nonchallenged) were immunized and challenged as described in Materials and Methods. At 14 weeks postimmunization (i.e., 6 weeks after an intrabursal challenge), all female mice were mated with proven breeder male mice to assess fertility. The experiment was repeated, and mice were sacrificed at several intervals to assess the immunopathological changes and the lymphoproliferative response. The following results were obtained with these experiments.
(i) C. trachomatis cultures. No chlamydia IFU were detected in the vaginal swab samples from the C. trachomatis-immunized, C. trachomatis-challenged or sham-immunized, nonchallenged animals (data not shown). On the other hand, cultures obtained from the sham-immunized, C. trachomatis-challenged mice became positive at day 64 postimmunization (4 days after challenge). At day 76 postimmunization, 63% of these mice were culture positive, and by the 84th day they were all culture negative.
(ii) Histopathological analyses. Mice were sacrificed, and their genital tracts were inspected for gross and microscopic morphological changes. In the sham-immunized, nonchallenged mice, no significant gross abnormalities were noticed throughout the period of observation and only a mild acute inflammatory infiltrate was noted microscopically at 71 days postimmunization that disappeared on subsequent examinations (data not shown). In the sham-immunized, C. trachomatis-challenged mice by day 71 (iii) Antibody response in serum. Figure 1 shows the kinetics of the serum antibody response in mice as measured by IFA in the three groups of mice. In the C. trachomatis-immunized, C. To clarify the reactivity to the 60-kDa region, an affinitypurified 60-kDa hsp from serovar A was probed with the mouse serum samples. No reaction to this protein was observed in the serum samples before intrabursal challenge from the C. trachomatis-immunized, C. trachomatis-challenged animals (data not shown). A positive band was detected by day 82 postimmunization (22 days after intrabursal challenge) that was also detected when tested at 109 days postimmunization. In the sham-immunized, C. trachomatis-challenged animals, a positive reaction to the 60-kDa hsp was detected on day 109 postimmunization (49 days after intrabursal challenge).
Western blot analyses of vaginal secretions showed a pattern similar to that of the serum samples, although in general the reactivity was weaker, delayed, and against a smaller number of chlamydial proteins (data not shown). Reactivity to the MOMP and 60-and 32-kDa proteins was detected in animals by 21 days after C. trachomatis immunization and remained positive for the rest of the experiment. Antibodies to the LPS were detected in the vaginal secretions by day 60 postimmunization.
(vi) Analysis of the B-cell response. The C. trachomatisspecific B-cell response as measured by the ELISPOT assay is shown in Table 3 . After intrabursal challenge in the C. trachomatis-immunized, C. trachomatis-challenged animals, the number of IgG-and IgA-specific ASCs gradually increased to 95 and 415 ASCs per 106 spleen cells, respectively, over a period of 2 weeks and remained elevated for the rest of the observation. The number of IgM-specific ASCs declined by day 82 postimmunization. In the sham-immunized mice after challenge with C. trachomatis, the number of IgG-and IgA-specific ASCs increased gradually and peaked at day 82, with 140 and 380 ASCs per 106 spleen cells, respectively, while the number of IgM-specific B cells decreased rapidly. In the sham-immunized, nonchallenged animals, 0 to 10 B cells were detected with the ELISPOT assay for any of the three Igs.
(vii) LPA. The results of the T-cell response as detected by the LPA are shown in Table 4 . No significant proliferation above background values was detected after culturing of T-cell-enriched spleen cells from sham-immunized, nonchallenged mice. At 71 days postimmunization, the counts per minute incorporated in response to the MoPn EBs in the C. trachomatis-immunized, C. trachomatis-challenged mice were six to seven times higher than those of the sham-immunized, nonchallenged mice and the sham-immunized, C. trachomatischallenged mice (P < 0.05). By day 95 postimmunization, the chlamydia-specific counts per minute of C. trachomatis-immunized, C. trachomatis-challenged and sham-immunized, C. (Table 5) . Of the eight mice in this group, six mice were unilaterally infertile and one mouse was bilaterally infertile. In contrast, 80% of the mice in the C. trachomatisimmunized, C. trachomatis-challenged group and 94% of the mice in the sham-immunized, nonchallenged group were bilaterally fertile (P < 0.05). The mean number of embryos in the sham-immunized, C. trachomatis-challenged animals was 1.6, while that in the sham-immunized, nonchallenged mice was 6.3 (P = 0.0002) and that in the C. trachomatis-immunized, C. trachomatis-challenged mice was 4.7 (P = 0.0358). No statistically significant difference in the mean number of embryos was found between the C. trachomatis-immunized, C. trachomatischallenged mice and the sham-immunized, nonchallenged animals (P = 0.252).
DISCUSSION
The results presented in this study indicate that immunization with viable C. trachomatis MoPn by the intranasal route can protect against infertility in mice upon challenge with this pathogen through the ovarian bursa. These results are very encouraging, since this is the first time that a vaccination protocol has been shown to protect reproductive function against a bacterial genital infection in a mammalian system.
The mechanisms involved in the sequelae that follow a chlamydial infection are not clearly understood. However, data from experimental models of trachoma suggest that crossreactivity between the host and the chlamydial 60-kDa hsp may lead to an autoimmune phenomenon (17, 18) . In addition, in patients with infertility or ectopic pregnancy, a high prevalence of antibodies to the 60-kDa hsp has been found (4, 8, 46 (30) and in the salpingitis model we describe here, no reactivity to the 60-kDa hsp by Western blots was observed after intranasal immunization, indicating that the dose and route of inoculation may be important or that the level of sensitivity of the Western blots is lower than that of the ELISA procedure used by Zhong and Brunham (50) . Furthermore, in the group of mice that we immunized intranasally with C. trachomatis, the subsequent challenge in the ovarian bursa did not lead to a decrease in fertility, indicating that if an autoimmune phenomenon had occurred it did not have functional sequelae in terms of tubal damage affecting fertility.
One of the great difficulties in the production of a vaccine against a genital infection is the induction of mucosal immunity. Fortunately, since all of the mucosal tissues are connected by the mucosal associated lymphoid tissue, stimulation of an immune response can occur locally or at a distal mucosal site (16) . Attempts to take advantage of this immunological network have been made by different investigators with the goal of protecting against a chlamydial genital infection. We decided to use the intranasal route for immunization because the C. trachomatis MoPn biovar is known to efficiently replicate in the lungs of mice and thus should be able to induce a strong immune response (49) . Murray et al. (19) showed that a primary eye infection with the guinea pig inclusion conjunctivitis serovar induced immunity to a challenge in the vagina and male urethra. Similarly, Nichols et al. (20) immunized guinea pigs by the intragastric route and were able to show protection against an ocular and a genital chlamydial challenge. More recently, Cui et al. (9, 10) also used the intragastric route to immunize mice against a chlamydial challenge by the nasal and genital routes. All of these investigators were able to elicit significant protection against a challenge, as shown by a decrease in chlamydial shedding, but in no instance were the effects of the vaccination on the long-term sequelae, namely infertility, ascertained. This is critical, since one of the primary goals in the case of chlamydial genital infections is to develop a vaccine that prevents infertility and ectopic pregnancy. A decrease in chlamydial shedding does not necessarily indicate that the long-term sequelae will be prevented, since upon challenge, infection, even though attenuated still occurs (34) . In this respect, Tuffrey et al. (44) observed that while in mice previously infected with C. trachomatis the period of shedding from the lower genital tract was shortened or shedding did not occur, salpingitis was more severe than in the control group, thus paralleling the previously reported adverse effects of a vaccine for trachoma (11, 35 immunity against future chlamydial infections. Thus, there is a window period, probably of only 15 to 20 years duration, when the immune response elicited by the vaccine will have to be efficacious in order to protect against infertility and ectopic pregnancy. It could be argued that, as in the case of trachoma, the incomplete protection provided by a weak vaccine may increase the deleterious effect of a genital infection, but this possibility will have to be further explored before a final conclusion can be reached. In addition, we would like to propose that if it is eventually confirmed that the sequelae secondary to a chlamydial infection are the result of an autoimmune disease resulting from cross-reactivity to the chlamydial 60-kDa hsp, the possibility of inducing tolerance to this protein should be considered as an alternative to vaccination.
In conclusion, this inbred mouse model of chlamydial salpingitis and infertility provides an excellent opportunity for investigating the immunopathogenesis of salpingitis and infertility as well as for testing chlamydial vaccines. As of now, it is not known whether in this model the infertility is due to the acute infectious episode, is the result of an autoimmune phenomenon, or is the consequence of other pathologic mechanisms. It is also not known if normal fertility rates could be maintained if a period of several months was allowed to lapse between the infection and the time of mating. Furthermore, in our experiments, we did not culture the genital tract after intranasal immunization, so we cannot be certain if the local immunity in the genital tract was the result of immunocompetent cells migrating from the lungs to the genital tract or if it was the result of a local infection in the genital tissues after intranasal immunization. Although our findings indicate that intranasally immunized mice develop both B-and T-cellmediated immune responses against C. trachomatis, the exact mechanisms and antigens involved in protection remain to be investigated. Results reported in the literature provide contradictory data on the factors involved in protection in chlamydial infections (3, 15, 25, (31) (32) (33) . Our data indicate that infertility could be prevented by intranasal immunization with replicating organisms. Thus, the chlamydial antigens involved in inducing a protective response and the components of the immune system required for protection may be further investigated with this model.
